Arcutis Biotherapeutics, Inc. cotiza a 26.22 USD y tiene una capitalización bursátil de $3.3B. En los últimos 12 meses ha facturado $464M con un margen de flujo de caja libre del -1.7%. Cotiza a 84.2 veces su flujo de caja libre (P/FCF) y a un PER de 115.6. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis,…
| Periodo | 2026-10 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.11 | $-0.09 | $0.13 |
| Estimado | $0.17 | $0.05 | $-0.06 | $0.09 |
| Sorpresa | — | +120.0% | -50.0% | +44.4% |
| Métrica | ARQT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 90.2% | 57.0% | +33.2% |
| Operating Margin | -3.3% | -38.6% | +35.4% |
| Net Margin | -4.3% | -33.6% | +29.3% |
| FCF Margin | -1.7% | -13.9% | +12.2% |
| ROE | -8.5% | -40.4% | +31.9% |
| ROA | -3.7% | -32.0% | +28.3% |
| Current Ratio | 3.17 | 2.84 | +0.33 |
| Debt / Equity | 0.58 | 0.28 | +0.30 |